Drug intelligence / Profile preview

abatacept + methylprednisolone

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of abatacept (a selective costimulation modulator that inhibits T cell activation) and methylprednisolone (a corticosteroid with anti-inflammatory properties). This combination is used in the treatment of rheumatoid arthritis, with methylprednisolone typically administered with the first three consecutive doses of abatacept to potentially achieve earlier remission and provide symptom relief while waiting for the biologic to take full effect.

Targets

GR (Glucocorticoid receptor)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)

Beyond the preview

Go deeper on abatacept + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abatacept + methylprednisolone.

Explore the full profile